Role of CD25 expression on prognosis of acute myeloid leukemia: A literature review and meta-analysis

PloS One
Jingyuan LiXinhua Zhang

Abstract

The gene expression for interleukin-2 receptor subunit alpha (CD25/IL2RA) is frequently altered in adults with acute myeloid leukemia (AML). Increasing evidence indicates that the elevated expression of CD25 may be correlated with poor survival for AML patients. Thus, we performed this meta-analysis to further evaluate the prognostic value of elevated CD25 in AML. Eligible studies were gathered by searching on PubMed, Web of Science, and Embase. Using the R language 3.6.0 software, Pooled hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS)/relapse-free survival (RFS)/event-free survival (EFS) for total and subgroup analyses were calculated to investigate the association of elevated CD25 and outcomes of AML patients. Ten studies with a total of 1640 participants were enrolled in this meta-analysis. Pooled HRs suggested that overexpression of CD25 predicted poor outcomes on both OS (HR = 2.27, 95%CI 1.95-2.64) and DFS/RFS/EFS (HR = 1.77, 95%CI 1.44-2.17) in overall population. Subgroup analyses stratified by ethnicity, AML subtype, cut-off value, statistical methodologies and detection method draw similar results. Our meta-analysis indicates that ele...Continue Reading

References

Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·D A FrankM E Greenberg
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Sep 3, 2004·Nature Reviews. Immunology·Thomas R Malek, Allison L Bayer
Mar 27, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Monique TerwijnGerrit Jan Schuurhuis
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roberta MortariniAndrea Anichini
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marina Y Konopleva, Craig T Jordan
Jun 15, 2011·Expert Review of Hematology·Edward Allan R Sison, Patrick Brown
Nov 3, 2012·British Journal of Haematology·Jan CernyRajneesh Nath
Oct 7, 2014·Leukemia·J J Ignatz-HooverD N Wald
Dec 3, 2014·Clinical Lymphoma, Myeloma & Leukemia·Tapan M KadiaHagop M Kantarjian
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Nov 27, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Irina SadovnikPeter Valent
Sep 9, 2016·Current Hematologic Malignancy Reports·Joshua P Sasine, Gary J Schiller
Jan 18, 2017·Hematology·Shin-Ichiro FujiwaraKeiya Ozawa
Feb 19, 2017·Pathology, Research and Practice·Xin ChenZhiMing Huang

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
Flow cytometry

Software Mentioned

R for
R language

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.